Navigation Links
The Lancet: New trial suggests cheaper drugs for common heart attack procedure could improve outcomes and save health budgets millions
Date:7/4/2014

A new study published in The Lancet compares outcomes for two drugs used to prevent blood clot formation during emergency heart attack treatment. The study suggests that use of one of the drugs, heparin, could result in improved outcomes (such as a reduced rate of repeat heart attacks), compared to the other drug tested, bivalirudin, which is in widespread use in high-income countries, and is around 400 times more expensive than heparin.

The results of the HEAT-PPCI trial suggest that systematic use of heparin rather than bivalirudin after primary percutaneous coronary intervention (PPCI) the most commonly used treatment for heart attack, which unblocks the arteries carrying blood to the heart could save health services substantial sums of money, at the same time as potentially improving patient outcomes.

Patients who undergo PPCI usually receive a combination of antithrombotic drugs to prevent any further blood clots forming during the procedure and after it has been completed. The most commonly used antithrombotic drugs are unfractionated heparin and bivalirudin, and although several previous trials have compared the two drugs, the evidence is unclear as to which drug results in better outcomes.

The trial took place at the Liverpool Heart and Chest Hospital in the UK, where 1829 patients undergoing emergency angiography (an x-ray examination of the heart's arteries after a suspected heart attack) were recruited to the trial. More than four fifths of these patients then went on to receive PPCI; approximately half received heparin, and half received bivalirudin. Researchers then recorded how many patients in both groups experienced a major adverse cardiac event, such as death or another heart attack, within 28 days after surgery.

The results show that overall rates of major adverse cardiac events were significantly lower in the group who received heparin, although the rates of adverse events were low, as expected, in both groups
'/>"/>

Contact: Matthew Back
matthew.back@lhch.nhs.uk
44-015-160-01423
The Lancet
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. The Lancet: Midwifery matters more than ever
2. The Lancet: UK has one of the highest death rates for children in western Europe
3. The Lancet: China halves tuberculosis prevalence in just 20 years
4. First evidence for painless atrial fibrillation treatment
5. ASPIRE Phase III trial of vaginal ring to prevent HIV completes enrollment of 2,629 women
6. GW leads clinical trial to reduce epileptic seizures in people with temporal lobe epilepsy
7. First first patient enrolled in PROSPECT II clinical trial
8. New definition of kidney disease for clinical trials could lead to new treatments
9. Trial uncovers potential dangers of chemotherapy regimen for bladder cancer patients
10. UH part of $7.5M NIH clinical trial on nearsightedness in children
11. Experimental trial represents promising step toward universal antidote for snakebite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , ... July 31, 2015 , ... There’s no better ... even when it comes time to cook the next meal, making July the most ... by practicing best grilling tips and recipes. , Make the next cookout different than ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... Those looking to catch a new and refreshing show on Broadway, look no ... and achievements including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille ...
(Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic Town has proven itself ... various plastic surgery procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and ... Botox and fillers. , Staying up to date with the latest cosmetic ...
(Date:7/31/2015)... ... 2015 , ... “Engage: Don’t Just Age” will be the ... symposiums, hosted by Massachusetts-based Harmony Healthcare International at Foxwoods Resort Casino in ... executives, administrators, directors of nursing, rehabilitation managers and other management and corporate personnel ...
(Date:7/31/2015)... ... July 31, 2015 , ... BioViva USA, Inc. (“BioViva”), ... we treat aging diseases. , BioViva announces it has begun a fundraiser through ... Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% of the money ...
Breaking Medicine News(10 mins):Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3
... Feb. 3 When Americans are asked about the ... Poll, commissioned by the,National Court Appointed Special Advocate (CASA) ... nothing about the experiences of children in,foster care, and ... these,children. When adults do think of children in ...
... and PACS Industry Veteran , Shawn Gibbons ... Compressus, Inc., leaders in healthcare IT systems interoperability ... of Janine Broda to chief marketing officer and ... president and general manager of the MEDxConnect(TM) division.Proven ...
... -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ... and distributor of high-quality,pharmaceutical grade glucose products ... invited to make a corporate presentation at ... Conference. , This ...
... are found to slow damage , , TUESDAY, Feb. 3 ... loss caused by Alzheimer,s disease, a new study says. ... University found that insulin acts as a shield that deflects ... responsible for forming memories. , "Therapeutics designed to ...
... Mich., Feb. 3 Perrigo Company,(Nasdaq: PRGO ; TASE) today announced results for its fiscal year 2009 second,quarter and six months that ended December 27, 2008. ... Perrigo Company, (in ... Second Quarter Six Months, ... 2009 2008 2009 ...
... MOUNTAIN VIEW, Calif., Feb. 3 MAP Pharmaceuticals, ... that the waiting period under the Hart-Scott-Rodino Act ... with AstraZeneca has expired, and the agreement is ... AstraZeneca will jointly develop and commercialize UDB, MAP ...
Cached Medicine News:Health News:National CASA Association Aims to Eliminate the Foster Care Stigma 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 3Health News:Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference 2Health News:Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference 3Health News:Insulin May Protect Against Alzheimer's 2Health News:Perrigo Reports Record Second Quarter Sales 2Health News:Perrigo Reports Record Second Quarter Sales 3Health News:Perrigo Reports Record Second Quarter Sales 4Health News:Perrigo Reports Record Second Quarter Sales 5Health News:Perrigo Reports Record Second Quarter Sales 6Health News:Perrigo Reports Record Second Quarter Sales 7Health News:Perrigo Reports Record Second Quarter Sales 8Health News:Perrigo Reports Record Second Quarter Sales 9Health News:Perrigo Reports Record Second Quarter Sales 10Health News:Perrigo Reports Record Second Quarter Sales 11Health News:Perrigo Reports Record Second Quarter Sales 12Health News:Perrigo Reports Record Second Quarter Sales 13Health News:Perrigo Reports Record Second Quarter Sales 14Health News:Perrigo Reports Record Second Quarter Sales 15Health News:Perrigo Reports Record Second Quarter Sales 16Health News:Perrigo Reports Record Second Quarter Sales 17Health News:Perrigo Reports Record Second Quarter Sales 18Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 2Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 3Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 4
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 2015 Future Market Insights (FMI) ... Glucose Monitoring Systems Market: Global Industry Analysis and Opportunity ... global continuous glucose monitoring systems market was valued at ... reach US$ 788.4 Mn by 2020, registering a CAGR ... Global continuous glucose monitoring systems market is ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... of Defense Continues Study of Copper as Effective ... Improving Indoor Air Quality, NEW YORK, Nov. ... determining the,antimicrobial effectiveness of copper, brass and bronze ... CDA President Andrew G.,Kireta Sr. Of the ...
... To Enroll 4,000 Patients Worldwide, MENLO PARK, ... it is launching a global Phase III clinical ... novel combination therapy CGT-2168.,The program, which includes the ... at hundreds of sites in the United States, ...
Cached Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy 2
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
Intermittent catheter - SpeediCath™ is pre-hydrated and ready to use right out of the package. Just open, cath and get on with your life....
The Medtronic® Resting Heart™ System offers a new approach to reducing cardiac surgery morbidity....
This adapter features a female luer on the single leg. A rigid "Y" has two legs with white clamps and terminate with male luers....
Medicine Products: